ADVM ADVERUM BIOTECHNOLOGIES INC revenue, earnings and financials
For the quarter ended September 30, 2025, ADVERUM BIOTECHNOLOGIES INC reported revenue of $0 (down 100.0% from a year earlier), net income of −$47.7M and diluted EPS of −$2.03; for the fiscal year ended December 2024 revenue was $1.00M, down 72.2% on the year before.
ADVM annual revenue and earnings
- Fiscal year ended Dec 2024: revenue $1.00M, gross profit n/a, operating income −$139M, net income −$131M (margin -13092.7%), EPS −$6.62
- Fiscal year ended Dec 2023: revenue $3.60M, gross profit n/a, operating income −$129M, net income −$122M (margin -3392.1%), EPS −$12.11
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$157M, net income −$155M (margin n/a), EPS −$1.56
- Fiscal year ended Dec 2021: revenue $7.50M, gross profit n/a, operating income −$146M, net income −$146M (margin -1940.5%), EPS −$1.48
ADVM quarterly revenue and earnings
- Quarter ended Sep 30, 2025: revenue $0 (down 100.0% year over year), net income −$47.7M, EPS −$2.03
- Quarter ended Jun 30, 2025: revenue n/a, net income −$49.2M, EPS −$2.34
- Quarter ended Mar 31, 2025: revenue n/a, net income −$47.0M, EPS −$2.25
- Quarter ended Dec 31, 2024 (from the annual report): revenue $0, net income −$40.9M, EPS −$1.96
- Quarter ended Sep 30, 2024: revenue $1.00M, net income −$32.4M, EPS −$1.55
- Quarter ended Jun 30, 2024: revenue $0, net income −$30.5M, EPS −$1.46
- Quarter ended Mar 31, 2024: revenue $0 (down 100.0% year over year), net income −$27.1M, EPS −$1.65
- Quarter ended Dec 31, 2023 (from the annual report): revenue $0, net income −$24.5M, EPS −$2.41
- Quarter ended Sep 30, 2023: revenue $0, net income −$33.4M, EPS −$3.31
- Quarter ended Jun 30, 2023: revenue $0, net income −$32.5M, EPS −$3.23
- Quarter ended Mar 31, 2023: revenue $3.60M, net income −$31.7M, EPS −$3.16
- Quarter ended Dec 31, 2022 (from the annual report): revenue $0, net income −$32.7M, EPS −$0.34
- Quarter ended Sep 30, 2022: revenue $0, net income −$40.1M, EPS −$0.40
- Quarter ended Jun 30, 2022: revenue $0, net income −$43.8M, EPS −$0.44
- Quarter ended Mar 31, 2022: revenue $0 (down 100.0% year over year), net income −$37.9M, EPS −$0.38
- Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$34.4M, EPS −$0.35
- Quarter ended Sep 30, 2021: revenue $0, net income −$38.4M, EPS −$0.39
- Quarter ended Jun 30, 2021: revenue $0, net income −$44.3M, EPS −$0.45
- Quarter ended Mar 31, 2021: revenue $7.50M, net income −$28.4M, EPS −$0.29
ADVM cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$92.5M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$90.9M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$108M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$108M, share buybacks n/a
ADVM balance sheet
- Sep 30, 2025: cash $26.1M, total assets $72.4M, total liabilities $128M, shareholders' equity −$55.7M
- Jun 30, 2025: cash $42.4M, total assets $96.2M, total liabilities $116M, shareholders' equity −$20.2M
- Mar 31, 2025: cash $49.2M, total assets $138M, total liabilities $111M, shareholders' equity $26.4M
- Dec 31, 2024: cash $60.7M, total assets $180M, total liabilities $109M, shareholders' equity $70.7M
- Sep 30, 2024: cash $92.9M, total assets $210M, total liabilities $102M, shareholders' equity $108M
- Jun 30, 2024: cash $127M, total assets $230M, total liabilities $92.2M, shareholders' equity $137M
- Mar 31, 2024: cash $150M, total assets $251M, total liabilities $86.9M, shareholders' equity $164M
- Dec 31, 2023: cash $75.0M, total assets $156M, total liabilities $88.5M, shareholders' equity $67.2M
What is ADVM's revenue?
ADVERUM BIOTECHNOLOGIES INC reported $1.00M of revenue for the fiscal year ended December 2024.
Is ADVM profitable?
No. ADVERUM BIOTECHNOLOGIES INC lost $185M over the last four quarters.
What is ADVM's EPS?
Diluted earnings per share over the last four quarters were −$8.58; −$2.03 in the latest quarter.